Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short-term Investments: 2013-2024

Historic Short-term Investments for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $70.0 million.

  • Amphastar Pharmaceuticals' Short-term Investments rose 2.69% to $59.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.9 million, marking a year-over-year increase of 2.69%. This contributed to the annual value of $70.0 million for FY2024, which is 37.75% down from last year.
  • As of FY2024, Amphastar Pharmaceuticals' Short-term Investments stood at $70.0 million, which was down 37.75% from $112.5 million recorded in FY2023.
  • Amphastar Pharmaceuticals' 5-year Short-term Investments high stood at $112.5 million for FY2023, and its period low was $10.3 million during FY2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Short-term Investments value was $70.0 million (recorded in 2024), while the average stood at $67.4 million.
  • Per our database at Business Quant, Amphastar Pharmaceuticals' Short-term Investments spiked by 472.16% in 2023 and then plummeted by 37.75% in 2024.
  • Amphastar Pharmaceuticals' Short-term Investments (Yearly) stood at $13.0 million in 2020, then dropped by 20.47% to $10.3 million in 2021, then surged by 90.54% to $19.7 million in 2022, then soared by 472.16% to $112.5 million in 2023, then plummeted by 37.75% to $70.0 million in 2024.